参考文献/References:
[1] Huang C,Wang Y,Li X,et al.Clinical features of patients infected with 2019 novel coronavirus in Wuhan,China[J].Lancet,2020,395(10223):497-506.DOI:10.1016/s0140-6736(20)30183-5.
[2] Wang L,Peng W,Zhao Z,et al.Prevalence and treatment of diabetes in China,2013-2018[J].JAMA,2021,326(24):2498-2506.DOI:10.1001/jama.2021.22208.
[3] Li B,Yang J,Zhao F,et al.Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China[J].Clin Res Cardiol,2020,109(5):531-538.DOI:10.1007/s00392-020-01626-9.
[4] Remuzzi A,Remuzzi G.COVID-19 and Italy:what next?[J].Lancet,2020,395(10231):1225-1228.DOI:10.1016/s0140-6736(20)30627-9.
[5] Guan WJ,Ni ZY,Hu Y,et al.Clinical characteristics of coronavirus disease 2019 in China[J].N Engl J Med,2020,382(18):1708-1720.DOI:10.1056/NEJMoa2002032.
[6] Seiglie J,Platt J,Cromer SJ,et al.Diabetes as a risk factor for poor early outcomes in patients hospitalized with COVID-19[J].Diabetes Care,2020,43(12):2938-2944.DOI:10.2337/dc20-1506.
[7] Letko M,Marzi A,Munster V.Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses[J].Nat Microbiol,2020,5(4):562-569.DOI:10.1038/s41564-020-0688-y.
[8] Muniyappa R,Gubbi S.COVID-19 pandemic,coronaviruses,and diabetes mellitus[J].Am J Physiol Endocrinol Metab,2020,318(5):E736-E741.DOI:10.1152/ajpendo.00124.2020.
[9] Avogaro A,Albiero M,Menegazzo L,et al.Endothelial dysfunction in diabetes:the role of reparatory mechanisms[J].Diabetes Care,2011,34(Suppl 2):S285-S90.DOI:10.2337/dc11-s239.
[10] Stegenga M,van der Crabben S,Blümer R,et al.Hyperglycemia enhances coagulation and reduces neutrophil degranulation,whereas hyperinsulinemia inhibits fibrinolysis during human endotoxemia[J].Blood,2008,112(1):82-89.DOI:10.1182/blood-2007-11-121723.
[11] Gomez-Peralta F,Abreu C,Gomez-Rodriguez S,et al.Safety and Efficacy of DPP4 Inhibitor and Basal Insulin in Type 2 Diabetes:An Updated Review and Challenging Clinical Scenarios[J].Diabetes Ther,2018,9(5):1775-1789.DOI:10.1007/s13300-018-0488-z.
[12] Raj VS,Mou H,Smits SL,et al.Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC[J].Nature,2013,495(7440):251-254.DOI:10.1038/nature12005.
[13] Vankadari N,Wilce JA.Emerging WuHan(COVID-19)coronavirus:glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26[J].Emerg Microbes Infect,2020,9(1):601-604.DOI:10.1080/22221751.2020.1739565.
[14] Meyer EJ,Gabb G,Jesudason D.SGLT2 Inhibitor-Associated euglycemic diabetic ketoacidosis:a south Australian clinical case series and Australian spontaneous adverse event notifications[J].Diabetes Care,2018,41(4):e47-e49.DOI:10.2337/dc17-1721.
[15] Khunti K,Knighton P,Zaccardi F,et al.Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes:a nationwide observational study in England[J].Lancet Diabetes Endocrinol,2021,9(5):293-303.DOI:10.1016/S2213-8587(21)00050-4.
[16] Singh AK,Singh R.Is metformin ahead in the race as a repurposed host-directed therapy for patients with diabetes and COVID-19?[J].Diabetes Res Clin Pract,2020,165:108268.DOI:10.1016/j.diabres.2020.108268.
[17] Zangiabadian M,Nejadghaderi SA,Zahmatkesh MM,et al.The efficacy and potential mechanisms of metformin in the treatment of COVID-19 in the diabetics:a systematic review[J].Front Endocrinol(Lausanne),2021,12:645194.DOI:10.3389/fendo.2021.645194.
[18] Bramante CT,Ingraham NE,Murray TA,et al.Metformin and risk of mortality in patients hospitalised with COVID-19:a retrospective cohort analysis[J].Lancet Healthy Longev,2021,2(1):e34-e41.DOI:10.1016/s2666-7568(20)30033-7.
[19] Gao J,Tian Z,Yang X.Breakthrough:Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies[J].Biosci Trends,2020,14(1):72-73.DOI:10.5582/bst.2020.01047.
[20] Wang M,Cao R,Zhang L,et al.Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus(2019-nCoV)in vitro[J].Cell Res,2020,30(3):269-271.DOI:10.1038/s41422-020-0282-0.
[21] Russell CD,Millar JE,Baillie JK.Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury[J].Lancet,2020,395(10223):473-475.DOI:10.1016/S0140-6736(20)30317-2.
[22] Hussain A,do Vale Moreira NC.Clinical considerations for patients with diabetes in times of COVID-19 pandemic[J].Diabetes Metab Syndr,2020,14(4):451-453.DOI:10.1016/j.dsx.2020.03.005.
相似文献/References:
[1]宋利革,李静,康志强.雌激素和新型冠状病毒肺炎的相关性[J].国际内分泌代谢杂志,2020,40(06):382.[doi:10.3760/cma.j.cn121383-20200306-03014]
Song Lige,Li Jing,Kang Zhiqiang.Correlation between estrogen and COVID-19[J].International Journal of Endocrinology and Metabolism,2020,40(03):382.[doi:10.3760/cma.j.cn121383-20200306-03014]
[2]迪丽清娜·迪力木拉提,张君宜,曲伸.肥胖对新型冠状病毒肺炎患者的影响[J].国际内分泌代谢杂志,2021,41(06):632.[doi:10.3760/cma.j.cn121383-20200706-07014]
Diliqingna·Dilimulati,Zhang Junyi,Qu Shen..Effects of obesity on patients with COVID-19[J].International Journal of Endocrinology and Metabolism,2021,41(03):632.[doi:10.3760/cma.j.cn121383-20200706-07014]
[3]相萍萍 韦晓 刘超.新型冠状病毒肺炎与糖尿病:我们何去何从?[J].国际内分泌代谢杂志,2022,42(01):50.[doi:10.3760/cma.j.cn121383-20201116-11033]
Xiang Pingping,Wei Xiao,Liu Chao..New coronavirus pneumonia and diabetes: Where shall we go?[J].International Journal of Endocrinology and Metabolism,2022,42(03):50.[doi:10.3760/cma.j.cn121383-20201116-11033]
[4]马思远,刘秉昆,石芳彬,等.维生素D在预防重症新型冠状病毒肺炎中的作用及价值[J].国际内分泌代谢杂志,2022,42(03):179.[doi:10.3760/cma.j.cn121383-20210329-03077]
Ma Siyuan,Liu Bingkun,Shi Fangbin,et al.Roles of vitamin D in the prevention of severie COVID-19[J].International Journal of Endocrinology and Metabolism,2022,42(03):179.[doi:10.3760/cma.j.cn121383-20210329-03077]